Mihail Obrocea

Mihail is a hematologist/oncologist with over 20 years’ experience in drug development in both academia and pharmaceutical/biotechnology industry with expertise in the development of cell therapy, cancer vaccines, monoclonal antibodies, and small molecules. Mihail has played an instrumental role in the development and commercialization of numerous drugs including IMBRUVICA,® Besponsa,® and BREYANZI.® Prior to joining MAIA, he served as Project and Clinical Lead at Atara Biotherapeutics where he supported the clinical development of the Atara’s allogeneic CAR T platform. Prior to that, he held multiple senior level positions over the last two decades including leading the Medical Affairs Oncology group at MedImmune, serving as VP, Clinical Development Oncology at MannKind Corp., Global Project Lead for AbbVie Biotherapeutics, Head, Medical Sciences at Pharmacyclics, VP of Clinical and Medical Affairs at SFJ Pharmaceutical Group, US Clinical Lead at Nanobiotix Corp, and clinical Program Lead at Juno Therapeutics Inc. Mihail’s research has been published in oncology peer-reviewed literature, he has co-authored published books related to cancer vaccines and immunology, and he holds several patents in the field of biotechnology.